J 2022

Sick leave duration as a potential marker of functionality and disease severity in depression

VOLZ, H. P., Eliška BARTEČKŮ, Lucie BARTOVA, J. BESSA, D. DE BERARDIS et. al.

Basic information

Original name

Sick leave duration as a potential marker of functionality and disease severity in depression

Authors

VOLZ, H. P. (guarantor), Eliška BARTEČKŮ (203 Czech Republic, belonging to the institution), Lucie BARTOVA (203 Czech Republic), J. BESSA, D. DE BERARDIS, J. DRAGASEK, H. KOZHUHAROV, M. LADEA, J. LAZÁRY, M. ROCA, G. USOV, A. WICHNIAK, B. GODMAN and S. KASPER

Edition

International Journal of Psychiatry in Clinical Practice, Oxon, TAYLOR & FRANCIS LTD, 2022, 1365-1501

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30215 Psychiatry

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.000

RIV identification code

RIV/00216224:14110/22:00126851

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/13651501.2022.2054350

UT WoS

000777522800001

Keywords in English

Absenteeism; depression; functionality; major depressive disorder; return to work; sick leave

Tags

14110222, rivok

Tags

International impact, Reviewed
Změněno: 16/1/2023 13:57, Mgr. Tereza Miškechová

Abstract

V originále

Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression. Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic. Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity. Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression.
Displayed: 15/11/2024 16:47